# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 31, 2023

# **GE HEALTHCARE TECHNOLOGIES INC.**

(Exact name of registrant as specified in its charter)

	Delaware	001-41528	88-2515116					
	(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)					
	500 W. Monroe Street Chicago, IL		60661					
	(Address of principal executive offices)		(Zip Code)					
	(Registrant's telephone	e number, including area code)	( <u>833) 735-1139</u>					
	(Former name or fo	rmer address, if changed since	last report.)					
	propriate box below if the Form 8-K filing is intended to see General Instructions A2. below):	simultaneously satisfy the filing	obligation of the registrant under any of the following					
	□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)							
,	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)							
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))							
□ Pre-com	imencement communications pursuant to Rule 13e-4(c	) under the Exchange Act (17 Cr	-R 240.13 <del>0-4</del> (0))					
Securities reç	gistered pursuant to Section 12(b) of the Act:							
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered					
Common stock, par value \$0.01 per share		G <del>EH</del> C	The Nasdaq Stock Market LLC					
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).								
			Emerging growth company □					
If an eme	If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.							
TICW OF TE	wisca inianidal accounting standards pursuant to section	in 10(a) of the Exchange Act.						

### Item 2.02 Results of Operations and Financial Condition.

On October 31, 2023, GE HealthCare Technologies Inc. ("GE HealthCare") issued a press release announcing its third quarter 2023 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K.

The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Description

Press release of GE HealthCare Technologies Inc., dated October 31, 2023.
 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.

## **SIGNATURES**

Pursuant to the requirement	ents of the Securities	Exchange Act of 1934	, the registrant has du	uly caused this r	eport to be signed	on its behalf by the
undersigned hereunto duly	y authorized.					

	GE HealthCare Technologies Inc.		
	(Registrant)		
Date: October 31, 2023	/s/ George A. Newcomb		
	George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)		